An Intermediate Expanded Use Trial of DFMO
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03581240 |
Expanded Access Status :
Available
First Posted : July 10, 2018
Last Update Posted : September 28, 2023
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Neuroblastoma Medulloblastoma Typical Teratoid Rhabdoid Tumor Embryonal Tumor With Abundant Neuropil and True Rosettes Ependymoblastoma Medulloepithelioma | Drug: eflornithine HCl |
Study Type : | Expanded Access |
Expanded Access Type : | Intermediate-size Population, Treatment IND/Protocol |
See clinical trials of the intervention/treatment in this expanded access record. | |
Official Title: | An Intermediate Expanded Use Trial of DFMO |
- Drug: eflornithine HCl
In this study subjects without CNS disease will receive oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID
Subjects with CNS disease will receive a dose of 2500 mg/m2/dose BID in order to facilitate crossing into the CNS.
Other Name: DFMO
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 0 Years to 30 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Age: 0-30 years at the time of initial diagnosis.
- Diagnosis: Histologic verification at either the time of original diagnosis or a previous relapse of High Risk neuroblastoma, medulloblastoma, atypical teratoid rhabdoid tumor, embryonal tumor with abundant neuropil and true rosettes, ependymoblastoma, medulloepithelioma and other rare pediatric MYC, ODC or LIN28/Let7 driven tumors (each type will form a new subset).
-
Disease Status: Subjects must be in one of the following disease categories:
- High risk neuroblastoma patients that have completed standard of care upfront therapy and are not eligible for NMTRC014.
- Medulloblastoma patients who have completed standard of care therapies.
- Relapsed/refractory neuroblastoma patients who have completed standard of care therapies.
- Rare tumors with increased LIN28 expression or MYCN amplification or up regulation of ornithine decarboxylase who have completed standard of care therapies.
- Subjects are not eligible to enroll on DFMO studies NMTRC002, NMTRC003, NMTRC010, or NMTRC014.
- A negative serum or urine pregnancy test is required for female subjects of child bearing potential (onset of menses or ≥13 years of age).
- Both male and female post-pubertal study subjects need to agree to use one of the more effective birth control methods during treatment and for six months after treatment is stopped. These methods include total abstinence (no sex), oral contraceptives ("the pill"), an intrauterine device (IUD), levonorgestrol implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended.
- Informed Consent: All subjects and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines
Exclusion Criteria:
- BSA (m2) of <0.25
- Investigational Drugs: Subjects who are currently receiving another investigational drug are excluded from participation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03581240
Contact: Genevieve Bergendahl, MSN | 7175310003 | gbergendahl@pennstatehealth.psu.edu |
United States, Pennsylvania | |
Penn State Milton S. Hershey Medical Center and Children's Hospital | Available |
Hershey, Pennsylvania, United States, 17033 | |
Contact: Suzanne Treadway streadway@hmc.psu.edu | |
Principal Investigator: Valerie Brown, MD |
Study Chair: | Giselle Sholler, MD | Beat Childhood Cancer |
Responsible Party: | Giselle Sholler, Study Chair, Milton S. Hershey Medical Center |
ClinicalTrials.gov Identifier: | NCT03581240 |
Other Study ID Numbers: |
NMTRC006 |
First Posted: | July 10, 2018 Key Record Dates |
Last Update Posted: | September 28, 2023 |
Last Verified: | September 2023 |
Neuroblastoma Medulloblastoma Rhabdoid Tumor Neuroectodermal Tumors, Primitive Neoplasms Neuroectodermal Tumors, Primitive, Peripheral Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue |
Glioma Neoplasms, Complex and Mixed Eflornithine Antineoplastic Agents Trypanocidal Agents Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents Ornithine Decarboxylase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |